We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
ESSA Pharma Inc | NASDAQ:EPIX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.20 | 2.63 | 6.50 | 0 | 09:16:35 |
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 1, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 8:00 a.m. Eastern Time in New York.
David R. Parkinson, President and Chief Executive Officer of ESSA Pharma; Peter Virsik, ESSA's Chief Operating Officer; and David S. Wood, ESSA's Chief Financial Officer, will host and participate in one-on-one meetings.
A live webcast of the Jefferies presentation can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com. Following the event, the webcast will be archived on the ESSA website for 90 days.
ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.comĀ and follow us on Twitter under @ESSAPharma.
View original content:https://www.prnewswire.com/news-releases/essa-pharma-to-present-at-2023-jefferies-healthcare-conference-301837354.html
SOURCE ESSA Pharma Inc
Copyright 2023 PR Newswire
1 Year ESSA Pharma Chart |
1 Month ESSA Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions